20121 2 1ChinJViralDisJanuary2012Vol.2No.1 11 : ; ; ; :R512.6+2 :C :2095-0136 (2012)01-0011-06 TechnicalguideforadulthepatitisBimmunizationinChina Chinese Prevention Medicine AsociationNationalImmunization ProgramChineseCenterfor DiseaseControland Prevention Corresponding author:liang Xiao-fengChineseCenterfor DiseaseControl and PreventionBeijing100050China.E-mail:liangxf@hotmail.com Keywords:HepatitisB;Adult;Immunologicaldefense;Technicalguide ( ) (HBV) HBV HBV 1992 HBV 1992 2006 <5 (HBsAg) HBV ; 30%~50% ( 5) HBV [2] HBV 6 HBV HBV [3] () 5 [4] 10% (HIV HBV ) HBV HBV DNA DNA [2-3] 25% HBV 42nm 3.2kb HBV DNA HBV (HCC);HBV HCC 10 5% HBV HBV HCC 100~300 [3] 4 [1] () 3~6 : 100050E-mail:liangxf@hotmail.com HBV 4 HBV (5%) HBV HBV 90% 25%~30%5%~ 1% 10d
12 20121 2 1ChinJViralDisJanuary2012Vol.2No.1 HBV HBV 3. : HBV [9] (FDA) HBV HBV HBV HBV -HBs [5] HBV HBV B ( HIV ) ( (AFP) HCC [6] HBV 1. : HBV HBV ( 8%) 30~40 HCC ; (2%~8%) HBV HBV ; (<2%)20~29 [10] 2005 [3] 120 25~45 79% (45~160)d 2 ; ( ) 5%16% HBV 40%~50% HBsAg HBV e (HBeAg) HBV [311] 2. :HBV [12] ( ) (MSM) HBV (1) : 40%~50% HBsAg [3811] HBV HBV HBV [3] HBsAgHBeAg () (2) :HBV [11] 70%~90% () HBV [8] HBV (2) : HBV ( ) (3) : HBsAg HBV ) ( ) HBV HBV 4. HBV : [11] HBsAg (1) : HBV (70%MSM 5 ) HBV HBV HBV (3) : HBV HBV HB-
20121 2 1ChinJViralDisJanuary2012Vol.2No.1 13 sag HBV HBV (4): (WHO) HBV (IVDAs) HIV HIV HBV 45% 24%43% [17] HBV HIV 6% ~15% MSM 9% ~17%IDUs 7%~10% 4%~6% [18] <5 (6) : HBsAg 0.96% ( 90%) [21-22] HBV HBV 5 ~ 14 HBsAg HBV 2.42%15~59 HBsAg HBV 6 HBV 2%~5% [11] 15~59 -HBs (7) : 47.38% [21] HBV 3. : HBV 2009 HBV 6 [2023] HBsAg ; HBV HBV (8) : 30 HBV 50% HCC 1. : HBV 1992 32% ;2002 [13] 21 ;2005 6 1 [19-20] (IDUs) HBV 24h 1 1 [14-15] 26 3 (CDC)2001-2005 HBV 16% [11] 6 HBV HBV IDUs64% (50%~ [16] 2009 81%) 1994-2001 (<15 ) <15 HBsAg (5)HIV : HIV HBsAg HBV HBV 22~29 MSM HIV 2. : 2006 1~59 HBsAg 7.18%1992 9.75% 26.36% [21] 8.57% HBsAg HBV 5%
14 20121 2 1ChinJViralDisJanuary2012Vol.2No.1 5%~20% [26] HBV 3 (1) / : ACIP 10~ 2600 2000 40μg [211] WHO CDC ( 20 ) [24] 95 20μg 0-1-6 1. : [27-29] / 18 20μg 0-18 1-6 : (1) : MSM HBsAg (2) : ( ) (2010 ) (3) : ( ) ( IDUs HBsAg ) HBV ( )IDUs (4) : HBV 0-1-6 20μg HIV 0-1-2-6 60μg 2. : 3 4. : 0-1-6 1 1 6 2 3 (3~6 ) HBIG 3 HBV 2 3 6 2 3 HBV 3. : [911] (2) : WHO CDC (HBIG) HBIG 120μg HBIG200~400IU (ACIP) 1 6 2 3 [25] 5. : HBV (-HBs< 10mIU/ml)
20121 2 1ChinJViralDisJanuary2012Vol.2No.1 15 : 3 3 2 3 1~2 -HBs 1 60μg 6.: ; Recomm Rep200655 (RR-16):1-33E1-E4. : ; ( amongyoungmenwhohavesexwithmen [J].AmJPublic ): [13] Health200191 (6):965-971. HauriAMArmstrongGLHutinYJ.Theglobalburdenof disease atributable to contaminated injections given in ; ( ): [1] Liaw YF.NaturalhistoryofchronichepatitisBvirusinfec- tionandlong-termoutcomeundertreatment [J].LiverInt 200929Suppl1:100-107. [2] MastEEMargolisHSFioreAEetal.Acomprehensive immunizationstrategytoeliminatetransmissionofhepatitis BvirusinfectionintheUnitedStates:recommendationsof theadvisorycommiteeonimmunizationpractices(acip) part1:immunizationofinfantschildrenandadolescents [J].MMWR Recomm Rep200554 (RR-16):1-31. [3] ShepardCWSimardEPFineliLetal.HepatitisBvirus infection:epidemiologyandvaccination [J].EpidemiolRev 200628 (2):112-125. [4] LaiCLRatziuVYuen MFetal.ViralhepatitisB [J]. Lancet2003362 (9401):2089-2094. [5] LokASMcmahonBJ.ChronichepatitisB:update2009 [J]. Hepatology200950 (3):661-662. [6] BruixJSherman M.Managementofhepatocelularcarcino- ma [J].Hepatology200542 (5):1208-1236. ChineseSocietyofHepatologyandChineseSocietyofInfec- tiousdiseaseschinese MedicalAssociation.Theguideline ofpreventionandtreatmentforchronichepatitisb (2010 version)[j].zhonghua Ganzang bing Zazhi201119 (1):13-24.(inChinese) 11-01].htp://www.who.int/csr/disease/hepatitis/Hep- atitisbwhocdscsrlyo20022.pdf. [10] YeDQ.Epidemiology [M].6thed.Beijing:People smedi- calpublishinghouse2006.(inchinese). [M].6 : [20] CuiFQGongXHChenYSetal.ChinesehepatitisBim-. munizationstrategiesandfeasibilityofexpandingthevacci- (2010 )[J]. nationtochildrenandhighriskpopulationamongadult[j]. 201119 (1):13-24. ZhongguoYimiaoHeMianyi200814 (6):553-558.(in [8] Alter MJ.EpidemiologyandpreventionofhepatitisB [J]. SeminLiverDis200323 (1):39-46. Chinese). [9] World Health Organization.HepatitisB [EB/OL].[2011- [J]. 2006. [11] MastEEWeinbaum CMFioreAEetal.Acomprehen- siveimmunizationstrategytoeliminatetransmissionofhep- tionsoftheadvisorycommiteeonimmunizationpractices (ACIP)Part I:immunization of adults [J].MMWR [12] MacKelarDAValeroyLASecuraGMetal.Twodecades aftervaccinelicense:hepatitisbimmunizationandinfection healthcaresetings [J].IntJSTD AIDS200415 (1): 7-16. [14] HouJLiuZGuFetal.Epidemiologyandpreventionof hepatitisbvirusinfection [J].IntJMedSci20052 (1): 50-57. atitisbvirusinfectioninthe UnitedStates:recommenda- [15] BialekSRBowerWAMotram Ketal.Riskfactorsfor hepatitisbinanoutbreakofhepatitisbanddamonginjec- tiondrugusers [J].JUrban Health200582 (3):468-478. mentin6 UScities [J].Am JPublic Health200292 (3):385-387. [16] MurrilCSWeeksHCastrucciBCetal.Age-specificse- roprevalenceofhivhepatitisbvirusandhepatitiscvirus infectionamonginjectiondrugusersadmitedtodrugtreat- [17] TienPCKovacsABacchetiPetal.Associationbetween syphilisantibodiestoherpessimplexvirustype2andrec- reationaldrug useand hepatitis B virusinfectioninthe Women sinteragency HIV Study [J].ClinInfect Dis 200439 (9):1363-1370. [18] AlterMJ.Epidemiologyofviralhepatitisand HIVco-infec- tion [J].JHepatol200644 (1Suppl):S6-S9. [19] ChineseSocietyofHepatologyandChineseSocietyofInfec- tiousdiseaseschinese MedicalAssociation.Theguideline ofprevention andtreatmentforchronic hepatitis B [J]. ZhonghuaGanzangbingZazhi200513 (12):881-891.(in Chinese). [J]. 200513 (12):881-891.
檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾 16 20121 2 1ChinJViralDisJanuary2012Vol.2No.1 200814 (6):553-558. [21] htp://www.chinacdc.cn/n272442/n272530/n3246177/23316. html. [22] CuiFQ.EpidemiologicalinvestigationofviralhepatitisBin Chinesepopulation:hepatitis B virusvaccination hasre- ducedhepatitisbvirusinfection [J].ZhongguoYimiao He Mianyi201016 (4):341-353.(inChinese). [27] ChiaramonteMMajoriSNgatchuTetal.Twodiferent [J]. dosagesofyeastderivedrecombinanthepatitisbvaccines:a 201016 (4):341-353. comparisonofimmunogenicity [J].Vaccine199614 (2): [23] ZhuangH.ProgressinepidemiologyofhepatitisB[J].Guowaiy- ixue Liuxingbingxue Chuanranbingxue Fence200431 (3):133-135.(inChinese). [J]. 2):57-67. 200431 (3):133-135. [29] ul-haqnhasnainssumarmetal.immunogenicityof [24] GuanZQDongZHWangQHetal.Costofchronichep- 10and20μghepatitisBvaccineinatwo-doseschedule[J]. atitisbinfectioninchina [J].JClinGastroenterol2004 Vaccine200321 (23):3179-3185. 38 (10Suppl3):S175-S178. [25] TheImmunizationPracticesAdvisoryCommitee(ACIP). Recommedationforprotectionagainstviralhepatitis [J]. MMWR198534 (22):302-335. [26] LiaoXYZhuangH.HepatitisBvaccinationwithoutscreen- ingissafe [J].Zhongguo Yufang YixueZazhi201011 (10):973-974.(inChinese). [J]. 201011 (10):973-974. 135-137. [28] AssadSFrancisA.Overadecadeofexperiencewithayeastre- combinanthepatitisbvaccine [J].Vaccine199918 (1/ :2011-12-10 : GB/T15835-1995 : : :84062 GB2312-80 [1987]93147 CN11-1399 21/22 HP-3000 85 B12